Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman’s disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately
HIV negative Castleman’s disease has been reported as a group of poorly understood lymphoproliferative disorder, and we want to explore the clinical feature and prognosis factors of CD.
We retrospectively collected the clinical information of 71 CD patients without HIV infection diagnosed in the first affiliated hospital of Zhengzhou university.
Different clinical classifications, including 35 patients (49.30%) with unicentric Castleman disease and 36 (50.7%) with multicentric Castleman disease, has their specific features compared with each other and unfavorable risk factors calculated by the univariate analysis. As for all of CD patients without HIV infection, there were 7 significant risk factors identified by the results of log-rank test, including clinical complaint, edema (hydrothorax, ascites, pelvic effusion), fatigue, anemia, hypoproteinemia and elevated serum β2-MG. Then, we created a Cox regression model of these clinical and statistic significant factors which indicated hypoproteinemia was an independent poor prognosis factors of CD in both univariate and multivariate analysis.
Our study emphasized the distinction of clinical characteristics between UCD and MCD and the importance of different poor risk factors of different clinical classifications which may directed more precise and appropriate treatment strategy.
KeywordsGiant lymph node hyperplasia Castleman disease HIV Hypoproteinemia Prognostic factors
X.L. and M.Z. designed the research; X.L. analyzed the data and wrote the paper; X.L. and Z.L. contribute to patient follow-up and data collection; Z.L. reviewed the pathological data.
This work was supported by a grant from the Natural Science Foundation, China (No. 81570203).
Compliance with ethical standards
Conflict of interest
The authors have no competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The ethical code is: science research-2015-LW-42. All patients in the study have consent for participation and provided follow-up record.
- Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Hall B, Velde H, Vermeulen J, Reddy M, Rhee F (2015b) Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease. Clin Cancer Res 21:4294–4304CrossRefPubMedGoogle Scholar
- Dong Y, Wang M, Nong L, Wang L, Cen X, Liu W, Zhu S, Sun Y, Liang Z, Li Y, Ou J, Qiu Z, Ren H (2015) Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol 169:834–842CrossRefPubMedGoogle Scholar
- Gérard L, Berezne A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E (2007) Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol 25:3350–3356CrossRefPubMedGoogle Scholar
- Hoffmann C, Schmid H, Muller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, Jager H, Bogner J, Arasteh K (2011) Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 118:3499–3503CrossRefPubMedGoogle Scholar
- Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959–3964CrossRefPubMedGoogle Scholar
- Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F (2000) High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 96:2069–2073PubMedGoogle Scholar
- Szturz P, Adam Z, Moulis M, Smardova L, Klincova M, Slaisova R, Koukalova R, Rehak Z, Volfova P, Chovancova J, Stehlikova O, Mayer J (2012) [Our experience in treatment of multicentric plasma-cell Castleman disease associated with vasculitis manifestations—case report and literature review]. Vnitr Lek 58:679–690PubMedGoogle Scholar
- Van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C (2014a) Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. The Lancet Oncology 15:966–974CrossRefPubMedGoogle Scholar
- van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C (2014b) Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15:966–974CrossRefPubMedGoogle Scholar
- Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH (2017) Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129:1658–1668CrossRefPubMedPubMedCentralGoogle Scholar